Confirmatory Trial of Segmentectomy for Clinical T1N0 Lung Cancer Dominant with Ground Glass Opacity based on Thin-section Computed Tomography (JCOG1211) - Confirmatory Trial of Segmentectomy for Clinical T1N0 Lung Cancer Dominant with Ground Glass Opacity based on Thin-section Computed Tomography (JCOG1211)

Japan Clinical Oncology Group (JCOG)0 个研究点目标入组 390 人开始时间: 2013年9月20日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) simultaneous or metachronous (within the past 5 years) double cancers other than carcinoma in situ or mucosal carcinoma. 2) active infection requiring treatment. 3) fever higher than 38 degrees C in axillary temperature. 4) women during pregnancy, possibility of pregnancy, or breast-feeding. 5) psychiatric disease. 6) systemic steroids or immunosuppressive medication. 7) diabetes mellitus treated with insulin or poorly controlled. 8) poorly controlled hypertension. 9) history of severe heart disease, heart failure, myocardial infarction within the past 6 months, attack of angina pectoris within the past 6 months, or multiple cardiac histories. 10) interstitial pneumonitis, pulmonary fibrosis, severe pulmonary emphysema, or multiple pulmonary comorbidities.

发起方

Japan Clinical Oncology Group (JCOG)